“Low Hanging Fruit” Keeps FDA Busy & Out of Pharma’s Social Media Hair
Another tidbit I picked up this week at CBI's 3rd Annual Forum on Social Media Regulations and Compliance is the notion that the FDA...
Branded Tweets Lacking ISI: What’s FDA’s Thinking on This?
This week, I attended CBI's 3rd Annual Forum on Social Media Regulations and Compliance in Alexandria, VA. Many of the medical/legal/regulatory (MLR) presenters and...
Pharma Urged to Employ Wikipedia Editors: Ain’t Goin’ to Happen
My friend, Dr. Bertalan Meskó (@Berci) writes (here):
Dear Pharma Companies,
The place of Wikipedia in the dissemination of medical information online is indisputable now. If...
Big Pharma Dumb ALECs: J&J, Pfizer, GSK, Bayer, Novartis, Merck, Daiichi Sankyo, Sanofi-Aventis, PhRMA
On June 6, ColorOfChange -- the nation’s "largest Black online civil rights organization" whose stated goal is to "strengthen Black America's political voice" --...
BI Dumps Celebrity COPD Spokesperson and Seeks Inspired Facebook Fans Instead
Today Boehringer Ingelheim (BI) sent out this tweet: "We have just launched a new #hcsm activity within Facebook....want to find out more? Check out...
Pfizer’s Deceptive “Campaign Against Migraine” Tweet Deleted – Too Late!
Sometimes, you make a mistake and want to "take it back." I understand that. But this electronically-connected world in which we live is making...
The Evolving Pharma-Physician Relationship
In this review of presentations made at the the PharmaMarketing Summit 2012, the common thread throughout is the evolving nature of the pharma-physician relationship, which is being transformed by the power of patients and payers, particularly aided and abetted by new emerging technologies.
Pharma Responds to FDA’s Draft DTC Guidelines
FDA has received several comments from the pharmaceutical industry regarding the agency's 'Draft Guidance for Industry Direct-to-Consumer Television Advertisements.' This article reviews the comments submitted by PhRMA, Sanofi, and Shire. Comments from other pharma companies addressed similar issues to the ones reviewed here.
Pfizer Throws In the Lipitor Marketing Towel. Meanwhile AstraZeneca Promotes Crestor on Its Corporate...
Despite Pfizer's heroic and unprecedented effort to maintain Lipitor's market share after expiry last November and after spending more than $87 million promoting the medicine, the world's biggest drug company is quietly giving up on its once-great cash cow for good because more generic versions will soon be going on sale. Meanwhile, AstraZeneca promoted Crestor on its corporate blog. It's unusual for a pharmaceutical company to mention a product by brand name on its corporate blog. It's even more unusual to mention BOTH the product AND its indication -- because that would be promotion regulated by the FDA. But AstraZeneca has done just that on its 'AZ Health Connections' corporate blog. Why now? Can it be a purely opportunistic cheap shot?
Exploring the 2.0 Doctor-Patient Relationship. The Impact of New Technologies on Healthcare
This article summarizes results of the 'Technology Impact on Healthcare' online survey. This article summarizes the survey results. The survey asked respondents to rate the importance internet tools and services in improving healthcare today and five years from now. Respondents also were asked to evaluate the impact of new technologies on public health problems such as obesity, vaccination, and smoking and which areas of the world are most active in developing and using health-related social media, mobile apps, and online communities. Finally, respondents were asked to identify which stakeholders -- government, technology companies, health-care professionals, patients, payors -- will be the major players online in 5 years.
